The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
By Brittney Nichols, MPH, RN-BSN, Science and Research Specialist, GO2 for Lung Cancer New treatments, developments, and scientific breakthroughs are always one of the most exciting aspects of the annual American Society of Clinical Oncology (ASCO) conference, but this [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
By Heather Law, MA, Associate Director, GO2’s Lung Cancer Registry Lung cancer screening is unavailable for many people at risk for lung cancer. At the 2023 American Society of Clinical Oncology (ASCO) meeting, early results from groundbreaking studies offered [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Many patients with non-small cell lung cancer (NSCLC) rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program One of the priorities of GO2 for Lung Cancer, alongside many other ally organizations, is to ensure that people diagnosed with lung cancer receive optimal care regardless of their background, [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those [...]
GO2 for Lung Cancer team pictured: Joelle Fathi, DNP, RN, ARNP, FAAN; Daniel Saez, MSc; Jennifer C. King, PhD By Jennifer C. King, PhD, Chief Scientific Officer and Daniel Saez, MSc, Manager, LungMATCH Navigation Program The [...]